For investors seeking momentum, State Street SPDR S&P Pharmaceuticals ETF XPH is probably on the radar. The fund just hit a 52-week high and rose 61.4% from its 52-week low price of $35.22/share.
But, are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook to get a better idea of where it might head:
The underlying S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the U.S. common stocks listed on the NYSE, AMEX, NASDAQ National Market and NASDAQ Small Cap exchanges. The Pharmaceuticals Index is a modified equal weight index. The product charges 35 bps in annual fees (See all Financials ETFs here).
With AI bubble fears doing rounds and the economy moving ahead at a sluggish pace, safe sectors like healthcare have been gaining precedence. Moreover, biotech stocks have been strengthening due to innovations and increased mergers and acquisitions.
Currently, XPH has a Zacks ETF Rank #3 (Hold) with a High risk outlook. However, it might continue its strong performance in the near term, with a positive weighted alpha of 39.32 (as per Barchart.com), which gives cues of a further rally.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
| Nov-12 | |
| Sep-08 | |
| Jul-31 | |
| Feb-26 | |
| Feb-18 | |
| Jan-29 | |
| Jan-28 | |
| Jan-16 | |
| Dec-24 | |
| Dec-10 | |
| Dec-09 | |
| Nov-28 | |
| Nov-27 | |
| Nov-18 | |
| Nov-14 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite